EGFR and neoplasm: It also exhibits good anti‐tumor effects in the organoids derived from patients with triple‐negative breast cancer.[189] The ongoing exploration of the potential of PROTACs and molecular glues will open exciting avenues for future research on targeting EGFR mutants.